Alyra Biotech is an Australian company focussed on developing new ways to reduce pelvic pain in women.

We have created a new IUD that may reduce the pain experienced by women after an IUD is inserted.

Alyra Biotech is undertaking two clinical trials of our novel intrauterine device and we welcome your involvement

 

OUR FIRST CLINICAL TRIAL – RECRUITING NOW

Our first clinical trial is for women who:

  • Live in Adelaide
  • Are between 18 – 45 years of age
  • Experience pain with periods and have regular monthly menstrual periods when they are not on the pill
  • Have had at least one child
    [IF YOU HAVE NOT HAD A BABY, YOU MAY BE ELIGIBLE FOR OUR SECOND TRIAL – SEE BELOW]
  • Are able to attend onsite visits to the PARC clinical trials unit at the Royal Adelaide Hospital
  • Are happy to record their symptoms on a study related APP each day
  • Have not had an IUD in the last 60 days

Participants will be paid an honorarium of $2000 for completion of the trial, receive a high quality ultrasound scan, and be provided with an individualised pain management plan at the end of the trial.

They will also have the excitement of contributing to a new area in women’s health that aims to provide new options for difficult to manage pain symptoms.

If you would like to find out more about the trial, please scan the QR code below or use the following link to fill in a quick eligibility survey:

 

Or CLICK HERE for the link to the Survey

*Study participation is voluntary, and you do not have to participate if you do not want to. Eligible participants will receive payment for time spent at the Clinic.

*All medical care will be provided by a specialist gynaecologist.

 

OUR SECOND CLINICAL TRIAL – RECRUITING AFTER THE FIRST TRIAL

This trial will be for women with period pain. There will be no need to have a baby.

Women in both Adelaide and Brisbane will be welcome to participate, and there will be fewer trial visits.

If you would like to be considered for the second trial, please scan the QR code, complete the questions, and remember to leave your contact details with us.

We will then contact you when the second trial begins.